North-2'-Deoxy-Methanocarbathymidines as Antiviral Agents Against Poxviruses


This invention relates to a method for the prevention or treatment of poxvirus infection by administering an effective amount of an antiviral agent comprising a carbocyclic 2'-deoxynucleoside analog (as described in U.S. Patent Nos. 5,629,454 and 5,869,666) to an individual in need thereof. North-methanocarbathymidine (N-MCT), a thymidine analog with a pseudosugar moiety locked in the northern conformation, which was previously shown to exert strong activity against herpes simplex virus types 1 and 2, has been identified as exhibiting potent activity against poxviruses. N-MCT effectively blocks poxvirus synthesis through its phosphorylated metabolite, which is more efficiently produced in poxvirus-infected cells. This compound is approximately seven times more potent than cidofovir against vaccinia and cowpox in cell culture. The higher potency and target specificity of N-MCT against poxvirus, as well as its high margin of safety, makes it a highly desirable agent against the poxviridae family. In addition, the mechanism of N-MCT may be different from that of cidofovir, making it even more desirable due to the scarcity of the potential available efficacious anti-pox agents currently under development. This method of treating poxvirus with the described analogs is now available for licensing.

Inventors:

Christopher Tseng (NIAID)  ➽ more inventions...

Victor Marquez (NCI)  ➽ more inventions...


Intellectual Property:
US Application No. 60/684,811
US Application No. 11/920,881
PCT Application No. PCT/US2006/020894
Various international patents issued

Licensing Contact:
Jenish Patel, Ph.D.
Email: jenish.patel@nih.gov
Phone: 240-669-2894

OTT Reference No: E-047-2005-0
Updated: May 15, 2018